Sickle cell disease (SCD) is a lifelong inherited blood disorder passed down through parental genes, characterized by the production of abnormal hemoglobin. As the oxygen-carrying protein in red blood cells, dysfunctional hemoglobin leaves the body’s tissues and organs chronically starved of oxygen. Unlike healthy red blood cells, which are round, flexible, and able to travel smoothly through blood vessels, SCD produces red blood cells that are rigid, sticky, and shaped like a crescent or farm sickle. These misshapen cells easily clump together, blocking blood flow and causing widespread damage throughout the body.
A key distinction is often drawn between sickle cell disease and sickle cell trait. People with sickle cell trait inherit just one abnormal hemoglobin S gene from one parent, paired with a normal gene from the other. While most carriers do not develop full symptoms of sickle cell disease, emerging research suggests some may experience mild symptoms, and all carriers are capable of passing the abnormal gene to their children. In Jamaica alone, approximately 10% of the population lives with sickle cell trait, a prevalence that has a direct impact on the number of children born with full sickle cell disease each year.
Marked annually on June 19, World Sickle Cell Awareness Day was created to expand public knowledge and global attention to this often-overlooked blood disorder. This year’s campaign centers on the theme “Closing the Survival Gap: Equity in Sickle Cell Disease”, representing a critical global shift from general awareness-raising to demanding tangible, systemic healthcare equity. The theme is anchored in four core pillars that guide global action.
The first pillar focuses explicitly on addressing the survival gap, targeting the stark global inequalities in life expectancy and health outcomes for SCD patients. The second pillar calls for equal access to high-quality care, demanding that consistent, high standards of diagnosis, pain management, and specialized treatment be available to all patients regardless of where they live. The third pillar shifts focus from awareness to action, challenging governments and healthcare systems to dismantle structural barriers to care rather than relying solely on educational outreach. The final pillar centers on empowering communities, calling for increased support for young patients and patient advocates to help them navigate care systems and confidently manage their condition.
The core objectives of the annual observance extend beyond these pillars to drive long-term change. Key goals include increasing public understanding of SCD’s global burden, encouraging national governments to integrate SCD care into public health programs and establish specialized treatment centers, and highlighting the critical role of pre-marital genetic screening in reducing intergenerational transmission of the abnormal gene. The day also advocates for expanded investment in research to improve quality of life for all people affected by SCD.
Symptoms of sickle cell anemia, the most common form of SCD, typically emerge around six months of age, varying between individuals and changing over time. One of the most debilitating symptoms is recurrent pain crises: when sickle-shaped cells block blood flow to the chest, abdomen, and joints, they cause extreme pain episodes that can last from a few hours to several days. While some patients experience only a few crises annually, others face a dozen or more, with severe crises requiring emergency hospital care. Many patients also live with chronic long-term pain caused by bone damage, joint damage, skin ulcers, and other SCD-related complications.
Anemia is another hallmark symptom of SCD. Healthy red blood cells live approximately 120 days before being replaced, but sickle cells break down and die in just 10 to 20 days, creating a persistent shortage of red blood cells that leaves patients chronically fatigued. Additional common symptoms include swelling of the hands and feet caused by blocked circulation, delayed growth and puberty in children and teenagers due to insufficient oxygen and nutrients for development, and vision damage when sickle cells block blood vessels supplying the retina.
The Caribbean region faces a disproportionate burden of SCD, a legacy of the Atlantic Slave Trade. Studies place the prevalence of sickle cell trait between 7% and 10% across the region, where most of the population of Caribbean islands traces their ancestry to West Africa. Outside of West Africa itself, the Caribbean has the highest incidence of sickle cell disease in the world, with the genetic variant linked to SCD originating predominantly from West African populations.
Modern treatment for SCD includes medication, blood transfusions, stem cell (blood or marrow) transplantation, and emerging gene therapy. To date, stem cell transplantation remains the only curative option for SCD, requiring a genetically matched donor, most commonly a sibling. Ongoing research is working to expand access to curative transplants by optimizing protocols for partially matched donors, such as parents or half-siblings. While SCD is associated with reduced life expectancy, new targeted treatments have dramatically improved both life expectancy and quality of life in recent decades. With optimal, consistent disease management, many people with SCD now live into their 50s and beyond.